abstract |
A pharmaceutical composition comprising Compound 1, (3-(6-(l-(2,2- difluorobenzo [d] [ 1,3 ] dioxol-5 -yl) cyclopropanecarboxamido)-3 -methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed. |